Education
About Us
Working with TipRanks
Follow Us
Lytix Biopharma AS (DE:6BG)
:6BG
6BG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.37 - €1.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€48.71M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding68,262,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lytix Biopharma AS News
PremiumCompany Announcements
Lytix Biopharma Grants Share Options to Board Members
PremiumCompany Announcements
Lytix Biopharma Reports Strong Q1 2025 Results and Strategic Advancements
PremiumCompany Announcements
Lytix Biopharma Strengthens Board to Boost Immuno-Oncology Focus
PremiumCompany Announcements
Lytix Biopharma Announces Board Chair Resignation Amid Strategic Developments
PremiumCompany Announcements
Lytix Biopharma’s LTX-315 Shows Promising Results as It Eyes Phase III TrialsPremiumCompany Announcements
Lytix Biopharma Secures U.S. Patent for Cancer TherapyPremiumCompany Announcements
Lytix Biopharma to Announce Q4 2024 Financial Results6BG FAQ
What was Lytix Biopharma AS’s price range in the past 12 months?
Lytix Biopharma AS lowest stock price was €0.37 and its highest was €1.04 in the past 12 months.
What is Lytix Biopharma AS’s market cap?
Lytix Biopharma AS’s market cap is €48.71M.
When is Lytix Biopharma AS’s upcoming earnings report date?
Lytix Biopharma AS’s upcoming earnings report date is Aug 28, 2025 which is in 95 days.
How were Lytix Biopharma AS’s earnings last quarter?
Lytix Biopharma AS released its earnings results on May 15, 2025. The company reported -€0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.016.
Is Lytix Biopharma AS overvalued?
According to Wall Street analysts Lytix Biopharma AS’s price is currently Overvalued.
Does Lytix Biopharma AS pay dividends?
Lytix Biopharma AS does not currently pay dividends.
What is Lytix Biopharma AS’s EPS estimate?
Lytix Biopharma AS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lytix Biopharma AS have?
Lytix Biopharma AS has 68,262,000 shares outstanding.
What happened to Lytix Biopharma AS’s price movement after its last earnings report?
Lytix Biopharma AS reported an EPS of -€0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.333%.
Which hedge fund is a major shareholder of Lytix Biopharma AS?
Currently, no hedge funds are holding shares in DE:6BG
Company Description
Lytix Biopharma AS
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.